Abstract 447P
Background
Hypomagnesaemia is a well-known side-effect in patients receiving cisplatin-containing chemotherapy. However, a small number of patients, who are receiving weekly cisplatin along with radiotherapy, will show symptoms. Till date in Bangladesh no study has been done to find out the incidence of hypomagnesaemia in concurrent chemo-radiotherapy patients.
Methods
This observational study was done between January, 2018 and February, 2019 at the Cancer Care Center of United Hospital Limited, Dhaka, Bangladesh. A total of 100 non-metastatic lung cancer patients were included in this study. Inclusion criteria were: patients treated with concurrent chemo-radiotherapy and weekly cisplatin; no prior chemotherapy; no prior kidney diseases; ECOG PS 1-2. All patients were treated with 40mg/m2 cisplatin weekly with radiotherapy. Radiotherapy doses were range in 60Gy to 70Gy in 2Gy per fraction. During chemotherapy 1000cc 0.9%NaCl saline was used as pre-hydration and post-hydration. Magnesium level was checked at week 1, week 3 and week 6. Events were categorized according common terminology criteria for adverse events v.4.0. In very severe cases IV magnesium was used, and in mild to moderate cases oral supplement has been used.
Results
Among 100 patients, 63 patients suffered various degrees of hypomagnesaemia. 23 patients were symptomatic for hypomagnesaemia and needed IV correction. And 27 patients were suffering from mild hypomagnesaemia. It has been observed that elderly patients suffer more; 41 patients were above the age of 60 years.
Conclusions
Although hypomagnesaemia is rarely symptomatic, it should be kept in mind that severe grade of hypomagnesaemia can cause fatal damage especially in elderly patients. As, Bangladesh is a developing country and accordingly to their food habits, people have low amounts of dietary magnesium as usual. This finding drives us, to change our daily practice to add IV magnesium (2.5mg/5ml) during post-hydration along with 20mmol potassium n weekly cisplatin chemotherapy to prevent hypomagnesaemia. This was a practice changing finding in our canter. To validate this observational finding we need large prospective multicenter data.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
274P - Treatment stratification of non-Hodgkin large B-cell lymphoma patients based on the identification of mutational c-MYC gene
Presenter: Raimkul Karakulov
Session: Poster display session
Resources:
Abstract
275P - Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: Preliminary results in Vietnam
Presenter: Gia Nguyen Hoang
Session: Poster display session
Resources:
Abstract
276P - Chronic myelod leukemia in chronic phase (CML-CP) with lymphadenopathy at diagnosis: A retrospective analysis
Presenter: GEDALA Veni Prasanna
Session: Poster display session
Resources:
Abstract
277P - Characteristics of BCR-ABL rearrangement variants in Pakistani patients with chronic myeloid leukemia and acute lymphocytic leukemia
Presenter: Zeeshan Ahmed
Session: Poster display session
Resources:
Abstract
278P - A systematic literature review of the cost-effectiveness of treatments, costs, and resource use in patients with Burkitt lymphoma
Presenter: Gautamjeet Mangat
Session: Poster display session
Resources:
Abstract
280P - Risk stratification of CML-CP in a real-world scenario, comparison of S.H.E. with rate of fall of BCR/ABL
Presenter: Kundan Mishra
Session: Poster display session
Resources:
Abstract
281P - Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine
Presenter: Jing Sun
Session: Poster display session
Resources:
Abstract
282P - Inhibition of miR-144 and miR-199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling
Presenter: Nidh Gupta
Session: Poster display session
Resources:
Abstract
283P - Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: A systematic review and meta-analysis
Presenter: Jinhyun Cho
Session: Poster display session
Resources:
Abstract